Straits Times Index
3,426.47 -3.98 (-0.12%) Nikkei
37,667.41 -202.10 (-0.53%) Hang Seng
17,021.31 +16.34 (+0.10%) FTSE 100
8,285.71 +99.36 (+1.21%) Bitcoin USD
67,820.57 +888.34 (+1.33%) CMC Crypto 200
1,372.22 +41.62 (+3.13%)
(NOT.HM)
| Previous close | N/A |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | 75.20 - 75.20 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 18 Jul 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Yahoo Finance Video
Novartis raises 2024 profit guidance, stock slipping though
Swiss pharmaceutical Novartis (NVS) is raising its full-year profit guidance after topping second quarter earnings and revenue estimates. Novartis' stock is slipping lower Thursday morning despite this positive news. Yahoo Finance senior health reporter Anjalee Khemlani details the pharma giant's outlook on its product pipeline as it positions itself more around sales of its heart failure drug Entresto. For more expert insight and the latest market action, click here to watch this full episode of Morning Brief. This post was written by Luke Carberry Mogan.
GlobeNewswireNovartis continues to deliver strong sales growth and core margin expansion in Q2; raises FY 2024 bottom-line guidance
Ad hoc announcement pursuant to Art. 53 LRQ2 net sales grew +11% (cc1, +9% USD) with core operating income up +19% (cc, +17% USD) Sales growth driven by continued strong performance from Entresto (+28% cc), Kesimpta (+65% cc), Cosentyx (+22% cc), Kisqali (+50% cc), Leqvio (+134% cc) and Pluvicto (+44% cc)Core operating income margin 39.6%, +270 basis points (cc), mainly driven by higher net salesQ2 operating income grew +47% (cc, +43% USD) and net income up +49% (cc, +43% USD)Q2 core EPS grew +2
- GlobeNewswire
Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML
Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR rates at week 48 vs. investigator-selected SoC TKIs (imatinib, nilotinib, dasatinib and bosutinib) (67.7% vs. 49.0%) and imatinib alone (69.3% vs. 40.2%)1 Scemblix also demonstrated a favorable safety and tolerability profile vs. imatinib and 2G TKIs, with fewer grade ≥3 AEs, dose adjustments, and half the rate of AEs leading to tr
